HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, agreed to acquire Genuity Science, a life science technology company, for $100m. "Our therapeutic programs have been identified through mechanistic insight into the role of the adaptive stress phenotype in cancer patients. Genuity’s AI/ML platform, which has successfully identified and validated novel molecular pathways in disease initiation and progression, is well positioned to further our understanding of the stress phenotype and its role in cancer progression," Alan Rigby, HiberCell Co-Founder and CEO.